Medical Marijuana Inc (OTCMKTS:MJNA) says that 2019 has been a great turn for it. That is considering the rise in sales bookings. The current figures beat those of the previous year by a significant margin.
A close outlook
This shouldn’t catch anyone by surprise! A lot of good things have been happening over recent years, and so this spike was expected. For instance, at the start of this year, the equity research firm Avise Analytics recognized the company’s efforts. It awarded it that Bronze Stevie® Award. This is usually given to that company that is consistently innovative. The business guru got this award during the 16th Annual International Business Awards conference. It says that it won’t stop in its efforts to make improvements to deliver the best products to consumers. Currently, the business is one of the first five leading CBD producers globally.
Turn of events
One outstanding attribute about this company and most of its subsidiaries is how they remain dedicated to progress. It was a short while back that the company announced that Kannaway® was making plans to establish its business presence in Japan. This happens to be one of its best-performing subsidiaries. It has showcased remarkable performance in the line of Healthcare Products and Services category. That is how it has become the recipient of the Silver Golden Bridge Award.
The CEO of Medical Marijuana is quite pleased with the progress. He thanks his team, saying that they contributed massively to this success. According to the official, the next best move will be to venture into the new markets. He is confident that there is a large market for the company’s wide range of products. The leader says that there is a large number of customers out there with versatile needs that must be met. They are targeting ramping up their business activities. The target is to rise and become one of the biggest players in the global cannabis industry segment.
Medical Marijuana remains committed to selling its products in Latin America, U.S, European, and the Asian markets. Subsidiaries such as Dixie Botanicals® and HempMeds® target serving consumers with topical, oral, and edible CBD products. The products sold are all tested.